China's new round of medical reforms and huge medical demand brought by the aging population make China's biomedical industry under the spotlight of foreign institutions. On March 16, the "Loncar China Biopharma Index (LCHINA)" set up by Loncar Investments, a well-known investment institution in the industry, was officially launched to track the development of China's biotechnology field. This is also the first public index to track the biomedical industry in Mainland China and overseas simultaneously.

The companies selected by LCHINA cover a wide range of types, including large pharmaceutical enterprises, emerging biotechnology enterprises, open biopharmaceutical technology platforms and diagnostic companies. They meet the three following requirements: First, they are all innovators in China's biomedical industry; second, they are all based in China, or the Chinese business takes up an important proportion; third, their financial sizes meet a certain threshold.

According to relevant reports, a total of 32 listed pharmaceutical companies land on the list including 24 Hong Kong-listed, as well as 8 Nasdaq-listed biopharmaceutical companies. Specially, the Hong Kong-listed companies include Fosun Pharma, CSPC Pharma, Sino Biopharmaceutical Limited, 3SBio Inc., Sinopharm Group Co., Ltd., Genscript Biotech Corporation, GrandPharma (China) Co., Ltd., China Resources Pharmaceutical Group Limited, CMS Group (00867), Shanghai Pharmaceuticals Holding Co., Ltd., Guangzhou Baiyunshan Pharmaceutical Co., Ltd., Luye Pharma Group Limited, SSY Group Limited, HEC Pharm, Livzon Pharmaceutical Group Inc., WuXi Biologics Cayman Inc., Haohai Biological Technology, BBI Life Sciences Corporation, Essex Bio-Technology Limited, China Pioneer Pharma Holdings Limited, Shandong Xinhua Pharmaceutical Company Limited, Sihuan Pharmaceutical Holdings Group Ltd., Lee's Pharmaceutical Holdings and Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

In the industry, it is not uncommon to set up a separate index, for example, NASDAQ Biotechnology Index and Loncar Cancer Immunotherapy Sector Index. Now, the LCHINA index joins them to witness together the recent rapid development of China's biomedicine industry.

"China's biopharmaceutical industry is on the cusp of comprehensive innovation, which will have a great impact on the world," said Mr. Brad Loncar, CEO of Loncar Investments, "Till today, however, there is still no sound index all over the world to keep track of this important trend. LCHINA has designed this index with global standards as benchmarks to quantify and track the exciting development of China's biotechnologies."

Source: Sina Finance